Literature DB >> 10721493

Human xenografts, human skin and skin reconstructs for studies in melanoma development and progression.

K Satyamoorthy1, F Meier, M Y Hsu, C Berking, M Herlyn.   

Abstract

Melanoma develops from a series of architectural and phenotypically distinct stages and becomes progressively aggressive. Considerable progress has been made in understanding the biological, pathological, and immunological aspects of human melanoma. Genetic and cytogenetic studies have revealed broad chromosomal abnormalities and wide mutational spectra. Precise biological and molecular determinants responsible for melanoma progression are not yet known. This is in part due to lack of experimental models that mimic human melanomas. Experimental models in melanoma should not only identify cause and origin of malignancy, but also should represent the ordered progression steps that culminate in metastasis to distant organs. Currently, there are several mouse and other vertebrate melanoma models under investigation; several of them promise to shed light on mechanisms of melanomagenesis. However, many of them suffer from lack of context to human skin architecture and hence, are of basic interest. The lack of appropriate models impeded the efforts to understand origin, etiology, progression and ultimately therapeutic benefits to humans. Development of human skin-mouse chimeric models has appeal because it mimics human diseases. In addition, human artificial skin constructs in vitro promises to be a versatile and efficient model to study not only origin and mechanisms of melanoma, but also progression. This review will focus on the recent progress in establishing tumor models in melanoma in general and their relevance to human melanoma as molecular determinants of tumor progression.

Entities:  

Mesh:

Year:  1999        PMID: 10721493     DOI: 10.1023/a:1006333627271

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  7 in total

1.  Comparing in vivo pump-probe and multiphoton fluorescence microscopy of melanoma and pigmented lesions.

Authors:  Jesse W Wilson; Simone Degan; Christina S Gainey; Tanya Mitropoulos; Mary Jane Simpson; Jennifer Y Zhang; Warren S Warren
Journal:  J Biomed Opt       Date:  2015-05       Impact factor: 3.170

Review 2.  [Relevance of cell culture models in cutaneous tumour biology: part II: complex culture systems].

Authors:  J Hatina; T Ruzicka
Journal:  Hautarzt       Date:  2008-02       Impact factor: 0.751

3.  Therapeutic implications of melanoma heterogeneity.

Authors:  Stephanie J Hachey; Alexander D Boiko
Journal:  Exp Dermatol       Date:  2016-05-19       Impact factor: 3.960

Review 4.  Chemoprevention of melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Adv Pharmacol       Date:  2012

Review 5.  Melanoma models for the next generation of therapies.

Authors:  E Elizabeth Patton; Kristen L Mueller; David J Adams; Niroshana Anandasabapathy; Andrew E Aplin; Corine Bertolotto; Marcus Bosenberg; Craig J Ceol; Christin E Burd; Ping Chi; Meenhard Herlyn; Sheri L Holmen; Florian A Karreth; Charles K Kaufman; Shaheen Khan; Sebastian Kobold; Eleonora Leucci; Carmit Levy; David B Lombard; Amanda W Lund; Kerrie L Marie; Jean-Christophe Marine; Richard Marais; Martin McMahon; Carla Daniela Robles-Espinoza; Ze'ev A Ronai; Yardena Samuels; Maria S Soengas; Jessie Villanueva; Ashani T Weeraratna; Richard M White; Iwei Yeh; Jiyue Zhu; Leonard I Zon; Marc S Hurlbert; Glenn Merlino
Journal:  Cancer Cell       Date:  2021-02-04       Impact factor: 31.743

6.  Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing.

Authors:  H Vörsmann; F Groeber; H Walles; S Busch; S Beissert; H Walczak; D Kulms
Journal:  Cell Death Dis       Date:  2013-07-11       Impact factor: 8.469

Review 7.  Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma.

Authors:  Thomas Bogenrieder; Meenhard Herlyn
Journal:  Crit Rev Oncol Hematol       Date:  2002-10       Impact factor: 6.312

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.